|
WO9835666A1
|
|
Formulations of nanoparticle naproxen tablets
|
|
US5834025A
|
|
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
WO9706132A1
|
|
Triiodoalkylphenyl esters as novel x-ray contrast agents
|
|
WO9704756A2
|
|
Methacrylate backbone surfactants in nanoparticulate formulations
|
|
US5668196A
|
|
3-amido-triiodophenyl esters as x-ray contrast agents
|
|
WO9628414A1
|
|
Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging
|
|
WO9625181A1
|
|
Process of preparing lymphography contrast agents
|
|
CA2207304A1
|
|
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
|
CA2212779A1
|
|
Compositions comprising nanoparticles of nsaid
|
|
US5643552A
|
|
Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
|
|
CA2193503A1
|
|
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanocrystal formulation
|
|
EP0766663A1
|
|
2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
|
|
US5573750A
|
|
Diagnostic imaging x-ray contrast agents
|
|
US5521218A
|
|
Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
|
|
TW401431B
|
|
Polyoxyalkylene block copolymers and a process for preparing them
|
|
US5552160A
|
|
Surface modified NSAID nanoparticles
|
|
US5565188A
|
|
Polyalkylene block copolymers as surface modifiers for nanoparticles
|
|
US5747001A
|
|
Aerosols containing beclomethazone nanoparticle dispersions
|
|
US5718919A
|
|
Nanoparticles containing the R(-)enantiomer of ibuprofen
|
|
US5543133A
|
|
Process of preparing x-ray contrast compositions containing nanoparticles
|
